MedTrace Logo

Testosterone in Metastatic Renal Cell Carcinoma Patients

NCT03379012 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-10-22

No results posted yet for this study

Summary

Purpose

To determine efficacy and safety of Testosterone in male patients with metastatic renal cell carcinoma and fatigue receiving targeted therapy or checkpoint inhibitors.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Testosterone undecanoate and sunitinib or pazopanib

Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)

Sponsors & Collaborators

  • Kidney Cancer Research Bureau

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-08
Primary Completion
2018-01-30
Completion
2019-07-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03379012 on ClinicalTrials.gov